Implement international harmonisation and work sharing activities with comparable international regulators. Enhanced cooperation and work sharing, including increased reliance on medicines evaluation and facilities inspection information from international regulators, as outlined in TGA’s International Engagement Strategy 2016-2018. Quantitative performance criteria 2015-16 Target 2016-17 Target 2017-18 Target 2018-19 Target 2019-20 Target Percentage of good manufacturing practice clearances of overseas manufacturers that take into account approvals by equivalent international regulators. 85% 85% 85% 85% 85% Program objective C. Promoting best practice regulation of therapeutic In 2016-17, the TGA will continue implementation of a comprehensive reform agenda that will optimise a range of regulatory processes and improve the way the TGA communicates with the public about the benefits and risks of therapeutic goods. The TGA will continue to identify opportunities and implement action to reduce regulatory burden on industry, consistent with the Government’s regulatory reform agenda, while continuing to meet the objectives of safeguarding and enhancing the health of the Australian community. Based on the Government’s response to the Expert Panel Review of Medicines and Medical Devices Regulation, the Department will begin design and implementation of the agreed reforms. Qualitative performance criteria 2016-17 Reference point or target Implement reforms that enhance TGA’s current regulatory processes and are consistent with the Government's regulatory reform agenda. Begin implementation of the Government’s response to the Review of Medicines and Medical Devices Regulation. Program objective D. Regulating the import, export, and manufacture of controlled The Office of Drug Control (ODC) will administer a licensing and permit regime for import, export and manufacture of controlled in line with Australian legislation and international conventions, to ensure access to essential medications while supporting Government policy on harm minimisation and harm reduction. Qualitative performance criteria 2016-17 Reference point or target Provide timely and quality advice to meet Australia’s reporting obligations the International Narcotic Drugs Conventions. Timely response to requests for data and completion of quarterly and annual reports. Quantitative performance criteria 2015-16 Target 2016-17 Target 2017-18 Target 2018-19 Target 2019-20 Target
Collect and disseminate data in the National Notifiable Diseases Surveillance System and monitor data quality in accordance with the National Health Security Act 2007. Data is collected and available for regular reporting by the Commonwealth and ad hoc requests by stakeholders, including publishing in the Department's journal Communicable Diseases Intelligence. Manage and control exotic mosquito populations to reduce the risk of disease transmission in the Torres Strait and mainland Australia. Regular mosquito surveillance to indicate whether the mosquito population has reduced in the target in the Torres Strait and not spread to the mainland. The development and spread of antimicrobial resistance (AMR) is minimised as a result of the National Antimicrobial Resistance (AMR) Strategy 2015-2019. Progress reports indicate that actions to minimise the development and spread of AMR are implemented in accordance with the National AMR Implementation Plan. Quantitative performance criteria 2015-16 Target 2016-17 Target 2017-18 Target 2018-19 Target 2019-20 Target Percentage of designated points of entry into Australia capable of responding to public health events, as defined in the International Health Regulations (2005). 100% 100% 100% 100% 100% Program objective D. Supporting the development of policies and implementation activities relating to health protection issues of national significance The Health Protection Program prevention, preparedness and response activities that protect the health of all Australians from threats posed by communicable disease outbreaks, natural disasters, environmental hazards, acts of terrorism and other incidents that may lead to mass casualties. Qualitative performance criteria 2016-17 Reference or target Establishment of the Health Protection Program to support the development of policies and activities relating to health issues of national significance comprising: Prevention; Preparedness; and Response. Implementation of the new Health Protection Program from 1 July 2016. Material changes to Program 5.2 resulting from the following measures: Health Flexible Funds – pausing indexation and achieving efficiencies Table 2.5.4 – Performance Criteria for Program 5.3 Program 5.3: Immunisation The Australian Government aims to protect the health of the community through immunisation initiatives. The Government recognises that immunisation is an effective way of protecting individuals and the Australian community, by reducing the spread of vaccine preventable disease. The
Quantitative performance criteria 2015-16 Target 2016-17 Target 2017-18 Target 2018-19 Target 2019-20 Target Number of completed tenders under the NPEV (Essential Vaccines Procurement Strategy). 2 3 1 1 1 Increase the immunisation coverage rates among children 12–15 months of age. 91.5% 92.0% 92.5% 93.0% 93.5% Increase the immunisation coverage rates among children 24-27 months of age. 91.5% 92.0% 92.5% 93.0% 93.5% Increase the immunisation coverage among children 60-63 months of age. 92.0% 92.5% 93.0% 93.5% 93.5% Increase the immunisation coverage rates among 12-15 months of age Aboriginal and Torres Strait Islander children. 87.0% 88.5% 89.0% 90.0% 90.5% Material changes to Program 5.3 resulting from the following measures: are no material changes to Program 5.3 resulting from measures.